Description
BSE notifies listing of 23,06,372 new equity shares of Eris Lifesciences Limited on a preferential basis to non-promoters, effective March 10, 2026, with a lock-in period until February 14, 2029.
Summary
BSE has notified trading members that 23,06,372 new equity shares of Eris Lifesciences Limited (Scrip Code: 540596, ISIN: INE406M01024) have been listed and are permitted to trade on the Exchange with effect from Tuesday, March 10, 2026. These shares were issued on a preferential basis to non-promoters at an issue price of Rs. 1835.35 per share (face value Rs. 1/- each, premium of Rs. 1834.35/-).
Key Points
- Company: Eris Lifesciences Limited (Scrip Code: 540596)
- Number of Shares: 23,06,372 equity shares of Rs. 1/- each
- Issue Price: Rs. 1835.35/- per share (premium of Rs. 1834.35/-)
- Allottees: Non-Promoters (preferential basis)
- Pari-passu: New shares rank pari-passu with existing equity shares
- Distribution Numbers: 137956022 to 140262393
- ISIN: INE406M01024
- Trading effective from: March 10, 2026
Regulatory Changes
No new regulatory changes. This is a standard listing notification pursuant to a preferential allotment already completed.
Compliance Requirements
- Trading members are informed to update their systems to reflect the new securities available for trading from March 10, 2026.
- The newly listed shares are subject to a lock-in restriction and cannot be traded until the lock-in period expires.
Important Dates
- Date of Allotment: January 16, 2026
- Trading Commencement: March 10, 2026
- Lock-in Period Expires: February 14, 2029 (all 23,06,372 shares under lock-in until this date)
Impact Assessment
The listing adds approximately 23.06 lakh equity shares to Eris Lifesciences’ tradeable float, representing a moderate equity dilution for existing shareholders. However, since all newly issued shares are under lock-in until February 14, 2029, there is no immediate increase in free-float or selling pressure. The preferential allotment at Rs. 1835.35/- per share indicates a capital raise at a significant premium, suggesting positive market sentiment or strategic investor participation. Market impact is expected to be minimal in the short term due to the lock-in constraint.
Impact Justification
Routine preferential allotment listing with lock-in; increases equity base by ~23 lakh shares at Rs. 1835.35, relevant to existing shareholders due to dilution and a 3-year lock-in on new shares.